Patents by Inventor Frédéric Colland

Frédéric Colland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20240042051
    Abstract: Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: November 23, 2021
    Publication date: February 8, 2024
    Inventors: Matthew T. Burger, Zhuoliang Chen, Joseph Anthony D'Alessio, Claudia Judith Klinter, Eric McNeill, Cornelia Anne Mundt, Katsumasa Nakajima, Richard Vaughan Newcombe, Mark G. Palermo, Tamas Schweighoffer, Bing Yu, Katharina Winkelbach, Qiang Zhang, Laura Bresson, Frédéric Colland, Ana Leticia Maragno, Francesca Rocchetti
  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20230092679
    Abstract: Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: May 19, 2020
    Publication date: March 23, 2023
    Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio
  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20230081720
    Abstract: Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: May 19, 2020
    Publication date: March 16, 2023
    Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio, John William Blankenship
  • 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER
    Publication number: 20220363677
    Abstract: Compounds of formula (I): wherein Het, Het1, Het2, A4, A5, Z1, R1, R2 and R3 are as defined in the description. Medicaments.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 17, 2022
    Inventors: Tibor NOVÁK, James Edward Paul DAVIDSON, Attila PACZAL, Jérôme-Benoît STARCK, András KOTSCHY, James Brooke MURRAY, Simon BEDFORD, Maïa CHANRION, Frédéric COLLAND, Mark Philip DODSWORTH, Andràs HERNER, Ana Leticia MARAGNO, Emma SANDERS, Mátyás Pál TIMÁRI, Paul WEBB
  • 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS
    Publication number: 20220289734
    Abstract: Compounds of formula (I): wherein Het1, Het2, R1, R2 and R3 are as defined in the description.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 15, 2022
    Inventors: James Edward Paul DAVIDSON, Tibor NOVÁK, Attila PACZAL, András KOTSCHY, Jérôme-Benoît STARCK, James Brooke MURRAY, Simon BEDFORD, Maïa CHANRION, Frédéric COLLAND, Patrice DESOS, Mark Philip DODSWORTH, Petra DUNKEL, Andràs HERNER, Zoltán MADARÁSZ, Ana Leticia MARAGNO, Márk MOLNÁR, Miklós NYERGES, Rachel Jane PARSONS, Monika RUDASOVÁ, Ágnes STROFEK, Marianna SZIGETI, Mátyás Pál TIMÁRI, Paul WEBB
  • BCL-2 INHIBITORS FOR USE IN THE TREATMENT OF A BCL-2 MEDIATED CANCER CARRYING THE GLY101VAL MUTATION
    Publication number: 20220211718
    Abstract: The invention relates to a Bcl-2 inhibitor for use in the treatment of a Bcl-2 mediated cancer carrying at least 1, 2, 3, 4, 5 or all of the following mutations: (i) Gly101Val; (ii) Asp103Tyr; (iii) Asp103Val; (iv) Asp103Glu; (v) Arg129Leu and (vi) Ala113Gly; wherein the Bcl-2 inhibitor is N-(4-hydroxyphenyl)-3-{6-[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide (Compound A) or 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-iH-pyrrole-3-carboxamide (Compound B), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 11, 2020
    Publication date: July 7, 2022
    Applicants: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: James Brooke MURRAY, Frèdéric COLLAND, Audrey CLAPERON
  • Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7
    Patent number: 9546150
    Abstract: The present invention relates to quinazolin-4-one compounds of formula (I?), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: January 17, 2017
    Assignee: HYBRIGENICS SA
    Inventors: Frédéric Colland, Marie-Edith Gourdel
  • Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications
    Patent number: 9328093
    Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 3, 2016
    Assignee: HYBRIGENICS SA
    Inventors: Roman Lopez, Frederic Colland
  • NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20150072973
    Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 12, 2015
    Inventors: Roman Lopez, Frederic Colland
  • Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7
    Publication number: 20140371247
    Abstract: The present invention relates to quinazolin-4-one compounds of formula (I?), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 18, 2014
    Applicant: HYBRIGENICS SA
    Inventors: Frédéric Colland, Marie-Edith Gourdel
  • Cysteine protease inhibitors and their therapeutic applications
    Patent number: 8648076
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 11, 2014
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Stefania Vallese, Matteo Colombo
  • NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20130023521
    Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
    Type: Application
    Filed: January 17, 2011
    Publication date: January 24, 2013
    Applicant: HYBRIGENICS SA
    Inventors: Roman Lopez, Frederic Colland
  • UBIQUITIN SPECIFIC PROTEASES RESPONSIBLE FOR MCL-1 STABILITY AND USES THEREOF
    Publication number: 20110237644
    Abstract: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.
    Type: Application
    Filed: October 29, 2009
    Publication date: September 29, 2011
    Applicants: Les Laboratoires Servier, Hybrigenics
    Inventors: Olivier Geneste, John Hickman, Frédéric Colland, Laurent Daviet
  • Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
    Publication number: 20110177105
    Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
    Type: Application
    Filed: August 13, 2010
    Publication date: July 21, 2011
    Inventors: Roman Lopez, Frédéric Colland
  • Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
    Patent number: 7875613
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: January 25, 2011
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20100048575
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use: Formula (I) wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1
    Type: Application
    Filed: October 25, 2007
    Publication date: February 25, 2010
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20090215786
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: July 26, 2006
    Publication date: August 27, 2009
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Stefania Vallese, Matteo Colombo
  • Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications
    Publication number: 20090181972
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 16, 2009
    Inventors: Philippe Guedat, Guillaune Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Ilaria Peretto, Stefano Vignando
  • Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
    Patent number: 7462615
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: December 9, 2008
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Ilaria Peretto, Stefano Vignando
  • NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20080103149
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1
    Type: Application
    Filed: October 30, 2006
    Publication date: May 1, 2008
    Inventors: Philippe GUEDAT, Xavier Jacq, Frederic Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo